Creative Biolabs' Therapeutic Antibody-coding mRNA Development Service is an innovative passive immunotherapy platform. It enables in vivo antibody production via the body's cells, bypassing ex vivo manufacturing and retaining natural biological fidelity, offering a scalable, rapid alternative to traditional protein infusions. With advanced mRNA design, optimized LNP delivery, and in vivo expression platforms, we accelerate drug discovery, reduce manufacturing costs by up to 1,000-fold, lower systemic toxicity, and deliver refined constructs for preclinical and clinical use.
Creative Biolabs specializes in developing therapeutic candidates that harness the high efficiency and transient nature of the mRNA platform.
We provide design and optimization services for a full spectrum of antibody formats, maximizing their therapeutic potential while minimizing safety risks:
Fig.1 The design diagrams of mRNA and antibodies currently used in the research include the basic structure of the constructs, possible different forms of mRNA, and other contents.1,3
Our robust workflow is designed to provide clear, milestone-driven progress, assuring optimal antibody expression and safety profiling for your therapeutic candidate.
Engineer synthetic mRNA sequences with N1-methylpseudouridine, optimized Cap1, UTRs, and mammalian cell-targeted codon optimization to boost translational efficiency, stability, and obtain high-purity, low-immunogenicity transcripts.
Perform high-quality IVT for optimized mRNA, apply stringent purification to remove dsRNA byproducts and contaminants, ensuring lot-to-lot consistency and stability.
Encapsulate purified mRNA into optimized LNPs, targeting the liver for expression and offering rational LNP designs for alternative biodistribution, like local or systemic lung delivery.
Test mRNA-LNP complexes in cell cultures to confirm antibody translation, folding, secretion, antigen-binding specificity, and in vitro activity vs recombinant protein benchmarks.
Evaluate final constructs in preclinical models, tracking mRNA-LNP biodistribution, antibody expression kinetics, and correlating mRNA dose with therapeutic dose.
Discover How We Can Help - Request a Consultation Today
The mRNA for constructing bispecific antibodies: The entire structure contains 5' Cap: Cap1 and N1-me-Ψ. The mRNA template contains 5' UTR, Kozak sequence, 3' UTR, and poly(A) tail, as well as the target coding sequence. The mRNA was transfected into HEK293 cells, and the bands of the expected molecular weight were detected from the supernatant by Western Blot assay. In addition, the specific binding of the target RNA to hEGFR was confirmed by ELISA experiments. Flow cytometry showed that the target RNA could bind to CD3 on mouse 2B4 T cells and EGFR on human CT26 EGFR cells, and had the ability to stimulate INF-γ.
Fig.2 Functional detection of mRNA-encoded bispecific antibodies.2,3
Experience the Creative Biolabs Advantage - Get a Quote Today
The mRNA platform offers a profound cost advantage, with the potential to reduce manufacturing costs by orders of magnitude (e.g., from tens of thousands of dollars to approximately $100 per dose). Furthermore, published data indicate that a low dose of an optimized mRNA-LNP can often achieve a significantly higher circulating antibody concentration in vivo than a much larger dose of recombinant protein, improving overall efficiency.
Absolutely. Our platform is optimized to encode and express a wide range of complex formats, including single-chain variable fragments (scFv) and multi-chain Bispecific T-Cell Engagers (TCEs). We specifically utilize this platform to design Fc-free versions of these potent molecules to ensure targeted activity and minimize systemic side effects.
We employ state-of-the-art engineering techniques, including the use of N1-methylpseudouridine (N1-me-Ψ) modified nucleosides to mask the mRNA from innate immune sensors (like TLRs), resulting in lower immunogenicity and higher translational yield. We also ensure rigorous purification protocols to remove immunogenic double-stranded RNA contaminants.
Antibody expression is designed to be transient. Peak expression typically occurs within 24 to 48 hours post-administration, with expression generally lasting for several days to over a week, depending on the mRNA design and the use of half-life extension fusion elements. This duration can be precisely controlled by our custom design strategies.
While the current generation of LNPs primarily targets the liver, Creative Biolabs is actively engaged in LNP engineering to achieve diverse biodistribution. We offer custom LNP formulations and modification strategies to explore localized delivery or target specific non-hepatic organs, such as the lungs or tumor microenvironment, depending on your clinical indication.
Creative Biolabs is committed to pioneering the next wave of antibody therapeutics through our specialized Therapeutic Antibody-coding mRNA Development Service. By combining unprecedented cost efficiency with high biological fidelity and advanced format engineering, we provide a pathway to rapidly deliver high-impact therapeutic candidates.
Contact Our Team for More Information and to Discuss Your Project
| Cat. No | Product Name | Promoter |
|---|---|---|
| GTVCR-WQ70MR | IVTScrip™ pSP6-VEE-mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11 Vector | SP6 |
| GTVCR-WQ71MR | IVTScrip™ pT7-VEE-mRNA-Anti-TYRP1, 20D7S Vector | T7 |
| GTVCR-WQ73MR | IVTScrip™ pSP6-VEE-mRNA-Anti-TYRP1, 20D7S Vector | SP6 |
| GTVCR-WQ76MR | IVTScrip™ pT7-VEE-mRNA-Anti-ANGPT2, 2xCon4C Vector | T7 |
| GTVCR-WQ78MR | IVTScrip™ pSP6-VEE-mRNA-Anti-ANGPT2, 2xCon4C Vector | SP6 |
| Cat. No | Product Name | Type |
|---|---|---|
| GTTS-WQ40MR | IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, Pseudo-UTP, 30 nt-poly(A)) | Antibody |
| GTTS-WQ41MR | IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, Pseudo-UTP, 30 nt-poly(A)) | Antibody |
| GTTS-WQ42MR | IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, Pseudo-UTP, 120 nt-poly(A)) | Antibody |
| GTTS-WQ43MR | IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) | Antibody |
| GTTS-WQ44MR | IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) | Antibody |
References
